PMID- 37458667
OWN - NLM
STAT- MEDLINE
DCOM- 20230719
LR  - 20230821
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 13
DP  - 2023 Jul
TI  - Prognostic role of intermountain risk score (IMRS) in intensive care unit 
      patients with a diagnosis of COVID-19.
PG  - 6437-6444
LID - 33005 [pii]
LID - 10.26355/eurrev_202307_33005 [doi]
AB  - OBJECTIVE: In this study, we aimed to assess the predictive value of 
      Intermountain Risk Score (IMRS) in intensive care unit (ICU) patients with 
      COVID-19. PATIENTS AND METHODS: Our retrospective study included the data of 194 
      patients who were admitted to the COVID-19 ICU of a tertiary care center. 
      COVID-19 diagnoses were made by a positive result from a real-time 
      reverse-transcriptase (RT) polymerase chain reaction (PCR) assay of nasal and 
      pharyngeal swab specimens. Patients who had negative RT-PCR results or who were 
      not admitted to ICU and patients under 18 years old were excluded from the study. 
      Complete blood count, biochemistry panel, and blood gas analysis results were 
      gathered and compiled. RESULTS: 194 ICU patients with COVID-19 (PCR positive) 
      were included in the study. The patients were divided into two groups according 
      to IMRS (if IMRS was <15 in women and <17 in men, patients were included in the 
      non-high-risk group, while patients with IMRS >/=15 in women and >/=17 in men were 
      defined as a high-risk group). Multivariate regression analysis was performed to 
      predict in-hospital mortality. The IMRS [OR: 1.17 (1.08-1.27) p<0.001)] was found 
      to predict in-hospital mortality. CONCLUSIONS: In this study, we showed that the 
      IMRS score at admission can predict in-hospital mortality in intensive care unit 
      patients with a diagnosis of COVID-19.
FAU - Cakir Guney, B
AU  - Cakir Guney B
AD  - Department of Internal Medicine, Sultan Abdulhamid Han Training and Research 
      Hospital, Istanbul, Turkey. dr.bskckr@gmail.com.
FAU - Ceneli, D
AU  - Ceneli D
FAU - Karagoz, A
AU  - Karagoz A
FAU - Serindag, Z
AU  - Serindag Z
FAU - Dogantekin, B
AU  - Dogantekin B
FAU - Cinar, T
AU  - Cinar T
FAU - Atis, O
AU  - Atis O
FAU - Tukel, N
AU  - Tukel N
FAU - Asal, S
AU  - Asal S
FAU - Sinlik, E
AU  - Sinlik E
FAU - Kaplan, M
AU  - Kaplan M
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - Male
MH  - Humans
MH  - Female
MH  - Adolescent
MH  - Prognosis
MH  - *COVID-19/diagnosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Intensive Care Units
MH  - COVID-19 Testing
EDAT- 2023/07/17 15:09
MHDA- 2023/07/19 06:43
CRDT- 2023/07/17 10:13
PHST- 2023/07/19 06:43 [medline]
PHST- 2023/07/17 15:09 [pubmed]
PHST- 2023/07/17 10:13 [entrez]
AID - 33005 [pii]
AID - 10.26355/eurrev_202307_33005 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6437-6444. doi: 
      10.26355/eurrev_202307_33005.